Press Releases Items Per Page 102550 Year None20212020201920182017201620152014 09-23-2021 Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy 09-22-2021 Daré Bioscience to Present at the 2021 Cantor Virtual Global Healthcare Conference 09-08-2021 Daré Bioscience to Participate in H.C. Wainwright 23rd Annual Global Investment Conference 09-07-2021 Daré Bioscience to Participate in Panel Discussion at Women’s Health Innovation Summit 09-01-2021 Daré Bioscience to Present at the 13th European Congress on Menopause and Andropause 08-12-2021 Daré Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update 08-09-2021 Daré Bioscience Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis 08-05-2021 Daré Bioscience to Host Second Quarter 2021 Financial Results and Company Update Conference Call and Webcast on August 12, 2021 07-26-2021 Daré Bioscience to Present at the 2021 Controlled Release Society Virtual Annual Meeting to be held July 25-29, 2021 07-12-2021 Daré Announces Collaborative Research Agreement (CRADA) for the Pivotal Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Contraceptive Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 28
09-23-2021 Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy
09-08-2021 Daré Bioscience to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
08-12-2021 Daré Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update
08-09-2021 Daré Bioscience Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis
08-05-2021 Daré Bioscience to Host Second Quarter 2021 Financial Results and Company Update Conference Call and Webcast on August 12, 2021
07-26-2021 Daré Bioscience to Present at the 2021 Controlled Release Society Virtual Annual Meeting to be held July 25-29, 2021
07-12-2021 Daré Announces Collaborative Research Agreement (CRADA) for the Pivotal Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Contraceptive
